Exciting New Data in Newly Diagnosed Multiple Myeloma

Exciting New Data in Newly Diagnosed Multiple Myeloma

Saved in:

Bibliographic Details
Main Author:	Kaveh Samii
Format:	Article
Language:	English
Published:	THE HEALTHBOOK COMPANY LTD. 2022-10-01
Series:	healthbook TIMES. Oncology Hematology
Online Access:	https://doi.org/10.36000/HBT.OH.2022.13.080
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Lymphopenia predicts poor outcomes in newly diagnosed multiple myeloma
by: Grace M. Ferri, et al.
Published: (2025-01-01)

Assessment and Treatment of Elderly Patients with Multiple Myeloma
by: Carmen de Ramon Ortiz, et al.
Published: (2024-06-01)

IMPeTUs parameters correlate with clinical features in newly diagnosed multiple myeloma
by: Shuaishuai Xu, et al.
Published: (2024-12-01)

Renal Dysfunction and Recovery following Initial Treatment of Newly Diagnosed Multiple Myeloma
by: Benjamin A. Derman, et al.
Published: (2018-01-01)

Herpes zoster prophylaxis: Essential for treating newly diagnosed multiple myeloma patients
by: Wen‐Ying Lin, et al.
Published: (2023-02-01)

MULTIPARAMETRIC FLOW CYTOMETRY REFINES RISK STRATIFICATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
by: Francesca Fazio, et al.
Published: (2023-08-01)

Implications of isolated MRD progression in newly diagnosed multiple myeloma treated with quadruplet therapy
by: Luciano J. Costa, et al.
Published: (2025-02-01)

Expression profile of Bcl‐2 family proteins in newly diagnosed multiple myeloma patients
by: Cristina De Ramón, et al.
Published: (2024-12-01)

The Rapidly Evolving Treatment Landscape in Newly Diagnosed Multiple Myeloma: Current Status and Future Directions
by: Yuxin Liu, et al.
Published: (2024-10-01)

Selinexor combined with bortezomib, lenalidomide, and dexamethasone for the treatment of newly diagnosed multiple myeloma with extramedullary disease
by: Junjing Yin, et al.
Published: (2024-11-01)

A Nomogram Based on Circulating Inflammatory Factors for Predicting Prognosis of Newly Diagnosed Multiple Myeloma Patients
by: Wang M, et al.
Published: (2025-02-01)

MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma
by: Manisha Bhutani, et al.
Published: (2025-02-01)

Cost-Minimization Analysis for Subcutaneous Daratumumab in the Treatment of Newly Diagnosed Multiple Myeloma in Three Gulf Countries
by: Anas Hamad, et al.
Published: (2024-07-01)

Clonal hematopoiesis impacts frailty in newly diagnosed multiple myeloma patients: a retrospective multicenter analysis
by: Elisa Gelli, et al.
Published: (2024-11-01)

Analysis of coagulation alteration and its correlation with β2-microglobulin in 371 patients with newly diagnosed multiple myeloma
by: Miao Hu, et al.
Published: (2024-12-01)

The correlation between serum bone metabolism indexes and bone disease and survival in newly diagnosed multiple myeloma patients
by: Linlin Huang, et al.
Published: (2024-12-01)

Incidental Discovery of Multiorgan Extramedullary Plasmacytomas in the Setting of Newly Diagnosed Multiple Myeloma and Delayed Hemolytic Transfusion Reaction
by: Joselle Cook, et al.
Published: (2017-01-01)

Real-world outcomes of maintenance therapy post-autologous stem cell transplantation in newly diagnosed multiple myeloma
by: Ka-Won Kang, et al.
Published: (2025-02-01)

Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China—Compared with bortezomib/lenalidomide/dexamethasone
by: Zhongjun Huo, et al.
Published: (2023-02-01)

Insights from Clinical Trials: Evidence-Based Recommendations for Induction Treatment of Newly Diagnosed Transplant-Eligible Multiple Myeloma
by: Olga Lytvynova, et al.
Published: (2024-09-01)

Cystatin C-Based Equations Detect Hidden Kidney Disease and Poor Prognosis in Newly Diagnosed Patients with Multiple Myeloma
by: Francisco-Javier Cepeda-Piorno, et al.
Published: (2022-01-01)

A stratified therapeutic model incorporated with studies on regulatory B cells for elderly patients with newly diagnosed multiple myeloma
by: Wenjiao Tang, et al.
Published: (2023-02-01)

Evaluation of the Prognostic Value of the Mayo Additive Staging System and Minimal Residual Disease in Newly Diagnosed Multiple Myeloma Patients
by: Yichuan Song, et al.
Published: (2024-11-01)

Daratumumab-based regimen for newly diagnosed multiple myeloma patients with paraskeletal plasmacytomas: a retrospective study in a single center
by: Shuiqing Xu, et al.
Published: (2024-12-01)

Duration of frontline therapy and impact on clinical outcomes in newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant
by: Sikander Ailawadhi, et al.
Published: (2023-02-01)

30‐Minute infusion of isatuximab in patients with newly diagnosed multiple myeloma: Results of a Phase 1b study analysis
by: Enrique M. Ocio, et al.
Published: (2024-11-01)

Impact of daratumumab on stem cell mobilization and transplant in patient with newly diagnosed multiple myeloma: a real word single-center study
by: Mauro Passucci, et al.
Published: (2024-04-01)

Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial
by: Hans Salwender, et al.
Published: (2024-12-01)

Use of Minimal Residual Disease Status to Reduce Uncertainty in Estimating Long-term Survival Outcomes for Newly Diagnosed Multiple Myeloma Patients
by: Naomi van Hest, et al.
Published: (2023-01-01)

Aberrantly expressed long noncoding RNAs as potential prognostic biomarkers in newly diagnosed multiple myeloma: A systemic review and meta‐analysis
by: Jiading Qin, et al.
Published: (2023-02-01)

Impact of lenalidomide-bortezomib-dexamethasone induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect® MM Registry
by: Sikander Ailawadhi, et al.
Published: (2024-11-01)

Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a systemic review and meta-analysis
by: Yin-Che Wang, et al.
Published: (2025-12-01)

Construction and validation of an 18F-FDG-PET/CT-based prognostic model to predict progression-free survival in newly diagnosed multiple myeloma patients
by: Xiaoqing Dong, et al.
Published: (2024-12-01)

Can you diagnose immune thrombocytopenia in myeloma? A case of thrombocytopenia in a patient with multiple myeloma
by: Cláudia Diogo, et al.
Published: (2024-11-01)

Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial
by: Roger Owen, et al.
Published: (2022-06-01)

Circular RNA_0003489 reflects unfavorable treatment response and shortened survival in newly diagnosed multiple myeloma patients who receive bortezomib-based induction therapy
by: Senhua Song, et al.
Published: (2024-12-01)

FEASIBILITY AND OUTCOME OF FIRST-LINE AUTOTRANSPLANT-BASED TREATMENT IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS AGED > 65 YEARS: MONOCENTRIC RETROSPECTIVE REAL-WORLD ANALYSIS
by: Paola Stefanoni, et al.
Published: (2024-08-01)

Calculated haemorheological profile and laboratory parameters in new diagnosed multiple myeloma patients: retrospective analysis according to survival
by: Melania Carlisi, et al.
Published: (2024-11-01)

Prevalence of comorbid autoimmune diseases and antibodies in newly diagnosed multiple sclerosis patients
by: Konstantin Fritz Jendretzky, et al.
Published: (2024-11-01)

Efficacy and safety of anti-CD38 monoclonal antibodies-based therapy versus standard therapy in newly diagnosed multiple myeloma patients: a systematic review and meta-analysis
by: Muhammad Osama, et al.
Published: (2025-01-01)